ONCAlert | Upfront Therapy for mRCC

Nivolumab/Ipilimumab Combo Extends Treatment-Free Survival in RCC

Jason Harris
Published Online: Jan 13,2020
Meredith M. Regan, ScD
Meredith M. Regan, ScD
All patients with advanced renal cell car­cinoma (RCC) assigned to nivolumab (Opdivo) plus ipilimumab (Yervoy) in the phase III CheckMate 214 trial had a longer treatment-free survival (TFS) than patients treated with sunitinib (Sutent). Furthermore, those patients assigned to the combination spent less time experiencing treatment-related adverse events (TRAEs).

Meredith M. Regan, ScD, an associate profes­sor of medicine at Harvard Medical School and an investigator in the Department of Data Sciences at Dana-Farber Cancer Institute, Boston, Massachu­setts, presented results from an analysis of data collected in CheckMate 214 during the 18th Interna­tional Kidney Cancer Symposium.1 Immuno-oncology agents have been shown to successfully extend sur­vival in many cancers, so physicians are now able to focus on improving patients’ quality of life, she said.

“When we look at the nivolumab/ipilimumab group versus sunitinib, the treatment-free time is about twice as long,” she said. “If we think about grade 3 toxicities, there is little time treatment-free with grade 3 or higher treatment-related adverse events.”

TFS is defined as the period between the end of first-line treatment and the start of subsequent therapy.

Patients in the nivolumab/ipilimumab arm received the combination every 3 weeks for up to 4 doses, followed by nivolumab alone every 2 weeks. Patients in the sunitinib arm received the agent once daily for 4 weeks of each 6-week cycle.

Treatment continued until disease progression, unac­ceptable toxicity, or patient decision.

In the overall population (N = 1082), the combina­tion was associated with a TFS of 6.8 months versus 2.9 months for sunitinib at a median follow-up of 30.0 months (95% CI, 2.4-5.3 months). TFS without TRAEs also favored the combination by 3.6 months for grade ≥3 TRAEs and 3.2 months for grade ≥2 TRAEs.

Among intermediate- and poor-risk patients, the combi­nation was associated with an improvement of about 2.6 months for TFS without grade ≥3 or grade ≥2 TRAEs.

Among favorable-risk patients, the combination induced a difference in TFS without toxicities of 6.8 months (9.4 vs 2.6 months) for grade ≥3 TRAEs and of 5.2 months (6.9 vs 1.8 months) for grade ≥2 TRAEs. The nivolumab/ipilimumab combination is not indicated for this population.

Regan noted that not only did the combination appear to improve TFS, but patients also had fewer toxicities during their time off treatment compared with those treated with sunitinib.

“We can see, especially in this time when patients are alive and doing well, how are they spending their survival time,” she said. “The dream is to treat a patient, get them off treatment, and allow them to go back to their life without having to be treated all the time and without having adverse effects of treatment.”

Regan added that TFS could represent a novel end point for clinical trials, which would change clinical trial design and drug development.

The FDA approved the nivolumab/ipilimumab combination in April 2018 based on results from CheckMate 214. Frontline treatment with the com­bination reduced the risk for death by 32% compared with sunitinib for patients with metastatic RCC. The risk reduction was 37% in patients with intermedi­ate- and poor-risk RCC, who constituted about 75% of the intent-to-treat population.

The median overall survival (OS) in the overall population was not reached with the combi­nation versus 32.9 months with sunitinib (HR, 0.68; 99.8% CI, 0.49-0.95; P = .0003). In patients with intermediate- and poor-risk RCC, the median OS was not reached in the nivolumab/ ipilimumab arm and was 26.6 months in the sunitinib arm (HR, 0.63; 99.8% CI, 0.44- 0.89; P <.0001). There was no benefit for the combina­tion versus sunitinib in those with favorable risk.

Previously, in CheckMate 067/069, TFS for patients receiving nivolumab plus ipilimumab was greater compared with nivolumab or ipilimumab alone, and time with persistent grade ≥3 TRAEs composed a small proportion of the TFS period for all treatments.2
 
 
References
  1. Regan MM, Atkins MB, Powles T, et al. Treatment free-survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma. Presented at: 18th International Kidney Cancer Symposium; November 15-16, 2019; Miami, Florida.
  2. Regan MM, Werner L, Rao S, et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition—a pooled analysis of patients with advanced melanoma [published online September 9, 2019]. J Clin Oncol. doi: 10.1200/JCO.19.00345. 



Clinical Articles

Nivolumab/Ipilimumab Combo Extends Treatment-Free Survival in RCC
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.